XenoPort to Present at the 24th Annual Piper Jaffray Health Care Conference

  XenoPort to Present at the 24th Annual Piper Jaffray Health Care Conference

Piper Jaffray Healthcare Conference 2012

Business Wire

SANTA CLARA, Calif. -- November 16, 2012

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentation at the 24th Annual Piper Jaffray Health
Care Conference. The live presentation will occur at 5:30 a.m. Pacific Time
(8:30 a.m. Eastern Time) on Wednesday, November 28, 2012. A replay of the
presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be
available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant^® (gabapentin
enacarbil) Extended-Release Tablets is approved in the United States for the
treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults
and for the management of postherpetic neuralgia in adults. GlaxoSmithKline
holds commercialization rights for Horizant in the United States during a
transition period ending on April 30, 2013, following which XenoPort will be
responsible for the further development, manufacturing and commercialization
of Horizant. Regnite^® (gabapentin enacarbil) Extended-Release Tablets is
approved and is being marketed for the treatment of RLS in Japan. Astellas
Pharma Inc. holds all development and commercialization rights for Regnite in
Japan and five other Asian countries. XenoPort holds all other world-wide
rights to gabapentin enacarbil. XenoPort’s pipeline of product candidates
includes potential treatments for patients with spasticity, Parkinson’s
disease and relapsing-remitting multiple sclerosis. To learn more about
XenoPort, please visit the Website at www.XenoPort.com.

XENOPORT, Horizant and Regnite are registered trademarks of XenoPort, Inc.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.